ALK and non-small cell lung carcinoma: The open-label randomized multicenter phase III trial involved 296 treatment-naïve patients with ALK-positive locally advanced and metastatic NSCLC, randomized to receive lorlatinib at a dose of 100 mg once daily or crizotinib.